NCT04724369View on ClinicalTrials.gov

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
Neuroblastoma
Interventions
DRUG

18F-MFBG

Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

The Children's Hospital of Philadelphia, Philadelphia

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children - Indiana University, Indianapolis

48109

University of Michigan Health System, Ann Arbor

90027

Children's Hospital Los Angeles, Los Angeles

94143

University of California, San Francisco, San Francisco

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

New Approaches to Neuroblastoma Therapy Consortium

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

INDUSTRY

NCT04724369 - Open-Label Study of 18F-mFBG for Imaging Neuroblastoma | Biotech Hunter | Biotech Hunter